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Polymers and boron neutron capture therapy
(BNCT): a potent combination
Anaïs Pitto-Barry *
Boron neutron capture therapy (BNCT) has a long history of unfulfilled promises for the treatment of
aggressive cancers. In the last two decades, chemists, physicists, and clinical scientists have been coordi-
nating their efforts to overcome practical and scientific challenges needed to unlock its full therapeutic
potential. From a chemistry point of view, the two current small-molecule drugs used in the clinic were
developed in the 1950s, however, they both lack some of the essential requirements for making BNCT a
successful therapeutic modality. Novel strategies are currently used to design new drugs, more selective
towards cancer cells and tumours, as well as able to deliver high boron contents to the target. In this
context, macromolecules, including polymers, are promising tools to make BNCT an effective, accepted,
and front-line therapy against cancer. In this review, we will provide a brief overview of BNCT, and its
potential and challenges, and we will discuss the most promising strategies that have been developed so
far.
Introduction
Boron neutron capture therapy (BNCT) is a two-component, or
binary, radiotherapeutic modality. BNCT was initially devel-
oped in the clinic in the 1950s by the neurosurgeon
W. H. Sweet, while its therapeutic potential was discovered by
Locher in 1936.1 Some nuclides have a high propensity for
absorbing low energy or thermal neutrons, and this is referred
to as the neutron capture cross-section. 10B is one of the most
attractive nuclides for neutron capture with a cross section of
3836 barns. It is a stable, non-radioactive isotope, with a
natural occurrence of 20%. The capture of thermal neutrons
by 10B leads to the production of high linear energy transfer
(LET) particles, alpha particles (He4) and recoiling lithium-7
nuclei (Fig. 1).2 The path lengths of these particles are limited
and approximately one cell in diameter (10–14 μm), and there-
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Fig. 1 Schematic representation of the nuclear reaction that happens
during the BNCT process. Reproduced from ref. 2 with permission from
Elsevier, copyright 2020.
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fore only cells that have internalised 10B are impacted by
irradiation. Indeed, the neutron capture cross section of hydro-
gen and nitrogen is weak enough to prevent any damage to
biological tissues from their reaction with thermal neutrons
(0.3326 and 1.91 barns, respectively). This nuclear reaction
leads to the destruction of a wide variety of biologically active
molecules (e.g., DNA, RNA, and proteins) whilst the surround-
ing tissues remain unaffected.
For successful BNCT treatment, a critical amount of 10B
and a sufficient number of thermal neutrons are therefore
needed to be delivered to individual tumour cells.
Ideal boron compounds should exhibit the following
characteristics:
- low systemic toxicity;
- low healthy tissue uptake and high tumour uptake;
- high tumour/blood and tumour/surrounding normal
tissue concentration ratios (greater than 3–4 : 1). This mini-
mises the impact that the capture of neutrons by hydrogen
and nitrogen, the two elements present in high concentrations
in the body, can have on the absorbed radiation dose;
- tumour concentrations of 20–35 μg of 10B per gram of
tumour, which accounts for 109 atoms of 10B per cell;
- rapid clearance from blood and normal tissues;
- persistence in the tumour for the duration of the treatment.3
This review will first introduce the early stages of BNCT in
terms of the compounds used, before focusing on high-mole-
cular weight polymeric systems that have been used for in vitro
and in vivo studies for potential BNCT applications.
First generation of compounds
The first boron-containing molecules used for BNCT were not
designed for such an application, but were selected because of
their availability, known pharmacology, and lack of toxicity.
Boric acid (H3BO3), sodium tetraborate (borax) and their
derivatives were initially used. The first experiments of
neutron irradiation were conducted on samples of mammary
carcinoma, lymphoma and undifferentiated sarcoma grown on
mice and infused with boronic acid. The tissues were shown
not to regenerate in vivo. These experiments carried out in the
1930–40s were the first demonstration that neoplastic cells
could be destroyed in vivo with BNCT treatment.4
Early clinical trials of BNCT were conducted in the US at
the Brookhaven National Laboratory Reactor using thermal
neutrons and sodium tetraborate during the 1950s on malig-
nant gliomas that were resisting all forms of treatment.5
Between severe damage of the scalp and no significant pro-
longation of survival nor evidence of therapeutic efficacy, clini-
cal trials in the US were stopped in 1961.6
Second generation of compounds
Following the poor clinical outcomes of the derivatives of boric
acid, a second generation of compounds was investigated,
initially in Japan for brain tumours from the late 1960s.7
Boron clusters with one or two sulfur atoms showed some
success, with the presence of the mercapto moieties being
hypothesised to allow binding to antibodies via a thiol–di-
sulfide exchange.8 Of these boron clusters, sodium borocap-
tate (BSH, Na2B12H11SH, Fig. 2) is the most promising owing
to its high and persistent boron concentrations in tumour and
low systemic toxicity even if it exhibits a low mean tumour/
blood ratio. p-Boronophenylalanine (BPA, Fig. 2) is another
compound which received a lot of interest, especially in the
treatment of malignant melanoma. Malignant melanoma cells
preferentially take up BPA because its chemical structure is
similar to that of tyrosine, which is required for melanogen-
esis. Other boron-containing amino acids were synthesised fol-
lowing the promising clinical trial results obtained for BPA.
Clinical trials have been carried out since the 1960s with
these second-generation compounds, either alone or in combi-
nation with another treatment regimen (surgery or radiother-
apy).9 Completed phase I/II studies have shown encouraging
results for difficult-to-treat and recurrent head and neck
cancers, melanoma, and gliomas (by intratumoural exposure)
in Japan, Taiwan, USA, and in several European countries
(Finland, Germany, Austria, France, and UK).10,11 Owing to the
progress of nuclear physics, it is now possible to produce low-
energy thermal neutrons using accelerators rather than
nuclear reactors.12 This has allowed for easier access to such
neutrons. For example, one recently reported phase II study
using BPA–10B has used BNCT in a Japanese urban hospital
setting on patients with unresectable carcinoma of the head
and neck, with very promising results.13
Despite this encouraging progress made by physicists and
clinicians, both BSH and BPA do not fulfil the criteria needed
for efficient boron delivery agents (e.g., poor uptake, low
selectivity between healthy and cancer cells). These com-
pounds were selected because they were the best benchmark
molecules available to gauge the progress made with the
technology. With better facilities and technical understanding
of the methodology, a third generation of compounds for
making BNCT a viable therapeutic modality was therefore
needed.
Third generation of compounds
Many boron delivery agents have been designed in the last few
decades, ranging from low- to high-molecular weight com-
Fig. 2 Chemical structures of BSH, a boron cluster (left), and BPA
(right).
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pounds to overcome the limitations of BPA and BSH, with a
focus on selective tumour cell targeting and the delivery of
therapeutic concentrations of boron. They can be classified
into three different types of boron-carriers: boron-containing
small molecules (which will not be discussed here), boron
compound conjugates and boron delivery nanoparticles
(Fig. 3). Many systems have also been designed to incorporate
biomolecules. This bioconjugation of synthetic (macro)mole-
cules with proteins has opened the way for the design and syn-
thesis of new molecules with enhanced chemical properties
and functions. Proteins, DNA, RNA or carbohydrates have been
derivatised for applications in ligand discovery, disease diag-
nosis, and disease treatment.14
Boron compound conjugates
Polymeric systems. The chemistry of boron is well estab-
lished to produce small molecules containing usually only one
boron, with the main focus of such molecules being towards
catalysis15 or functional nanostructured materials.16,17
However, most polymeric systems developed with BNCT in
mind use carborane derivatives as boron compounds, owing to
their rich boron composition.
Carborane-conjugated polymers are of high interest for
designing potential agents for BNCT. After their initial work
on the direct incorporation of carborane moieties in well-
defined macromolecules by living free-radical polymerisation
and sequential dendrimer synthesis,18 Adronov and co-
workers designed, in 2005, a carborane acrylate monomer that
could be copolymerised by atom transfer radical polymeris-
ation (ATRP) to obtain water-soluble polymers. Whilst no bio-
logical studies were conducted, the different synthesised
materials were tested for their neutron irradiation potential
and showed the release of gamma radiation, thus confirming
their potential as neutron capture systems.19
In 2016, Huang and co-workers synthesised amphiphilic
carborane-conjugated polycarbonates by ring-opening poly-
merisation of a carborane cyclic carbonate monomer onto a
poly(ethylene glycol) macroinitiator (Scheme 1).20 The boron
content was tuned by varying the ratio between the two blocks
and the molecular weight of the initiator. Different sizes of
polymeric micelles were obtained; the larger ones (diameter of
150 nm) showed more capture by the liver despite the PEG
chains on the shell, while the smaller ones (diameter of
50 nm, with shorter PEG chains) were more likely to be inter-
nalised into cancer cells. No toxicity was observed for the
range of nanoparticles on normal mouse fibroblast L929 cells
and human cervical cancer HeLa cells, while the carborane-
containing monomer exhibited a 50% inhibitory concentration
of 1.8 mM on L929 cells which is higher than other small
molecules with carborane entities.21 Finally, BNCT experi-
ments were performed on mice bearing U14 tumours (mouse
cervical cancer cell line) after sufficient injection of the
micelles was established. No reduction of tumour volume was
observed without irradiation, while an irradiation time of one
hour led to significant shrinking of the tumours. Importantly,
mice did not lose weight for over 21 days after irradiation.
In 2016, the radical addition–fragmentation chain-transfer
(RAFT) technique was used to polymerise a carborane-contain-
ing methacrylate monomer onto a poly(caprolactone) (PCL)
macroinitiator.22 A further block made of oligo(ethylene
glycol)methyl methacrylate (OEGMA) was then added to obtain
an amphiphilic triblock copolymer that was functionalised on
the alcohol end group of the PCL block with a near-infrared
aminocyanine dye (Fig. 4). Indeed, imaging-guided BNCT is
crucial to determine the distribution of carborane-containing
nanoparticles in the body and their accumulation within
organs and organelles. The biocompatibility of the micelles
obtained by solvent displacement was determined against
hepatic cancer and normal cell lines and low cytotoxicity was
observed in both cases (cell viability of more than 90% up to
0.5 g mL−1). In vitro fluorescence studies showed that the dye
accumulated in the cytoplasm of cells, which hints at the suc-
Scheme 1 Structure of the amphiphilic carborane-conjugated polycar-
bonate and self-assembly in water, adapted from ref. 20 with permission
from the American Chemical Society, copyright 2016.
Fig. 4 Structure of the amphiphilic poly(carborane-containing meth-
acrylate)-b-poly(caprolactone) with or without a near-infrared amino-
cyanine dye.
Fig. 3 Overview of the various polymeric systems containing boron,
either conjugated or encapsulated, and the possible conjugation to tar-
geting or labelling moieties: (A) micelles made from polymers or den-
dronised polymers; (B) dendrimers; and (C) liposomes.
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cessful accumulation of the polymeric boron-containing
micelles in the cytoplasm, even if no degradation studies to
look at the stability of the micelles were conducted.
In 2014, Wu and co-workers used a slightly different
approach to produce polymeric nanoparticles by mimicking
the structure of a small surfactant with the carborane unit as
the hydrophobic head covalently linked to a PEG2000 unit, the
hydrophilic tail, via the thiol–ene reaction.23 Such polymeric
chains were further labelled with the hydrophilic rhodamine B
dye on a second available position on the carborane unit
(Scheme 2). Self-assembly by solvent displacement led to vesi-
cles with a diameter of around 160–170 nm and a shell thick-
ness of 10 nm, depending on the absence or presence of the
dye. The vesicles did not exhibit cytotoxicity on HepG2 cells
(liver cancer cells) and had a much longer in vivo circulation
time (60% after 24 h) than BSH alone (20%) or other carbor-
ane-containing PEG formulations. In vitro fluorescence studies
on U87 cells (glioblastoma cancer cells) showed the accumu-
lation of the dye in the cytoplasm. Using fluorescence
microscopy after intravenous injection of a saline solution of
the fluorescent vesicles, the vesicles were found to accumulate
in the spleen of mice but not in other organs (heart, liver,
kidney), which confirms their potential as drug delivery
systems.
In 2019, Tsukahara and co-workers coated the surface of a
vesicle with a copolymer containing a 2-methacryloyloxyethyl
phosphorylcholine zwitterionic block and a methacrylamide
benzoxaborole second block which, at pH above 7.6, forms
ionised B(OH)2
− groups capable of binding to monosacchar-
ides such as galactose (Fig. 5).24 The vesicle used is the hemag-
glutinating virus of Japan Envelope (HVJ-E) which is a non-pro-
liferative and non-infectious vesicle utilised as a “non-viral”
transfection reagent based on its high cell-fusion affinity.
Unusually, this system did not use the capability of vesicles to
load materials within their internal core.25 The polymer was
synthesised by free radical polymerisation, purified by dialysis
and freeze-dried before being used for the coating of HVJ-E.
The obtained bioconjugates were still of a spherical shape and
dilution of the solution did not affect the diameter of the bio-
conjugates. 107–108 atoms of boron were found to be on the
surface of one particle, which means only a few bioconjugates
need to bind to one cell to reach the needed 109 boron atoms
per cell for efficient boron neutron capture. The polymer gen-
erated no apparent cytotoxicity on HepG2 cells (human liver
carcinoma cells). In vitro fluorescence studies of the bioconju-
gates revealed that the intracytoplasmic localisation of the
polymer took between 45 and 90 minutes. No in vivo or BNCT
experiments have been reported so far using this system.
Recently, amphiphilic diblock copolymer nanoparticles
with a boron-rich core have been synthesised by RAFT-
mediated polymerisation-induced self-assembly (Fig. 6).26 A
methacrylic monomer with a pinacol boronate ester was
polymerised by RAFT onto various hydrophilic POEGMA
blocks used as macromolecular transfer agents to produce
sub-100 nm spherical polymeric micelles. Nanoparticles were
shown to be non-cytotoxic up to a concentration of 100 μg
mL−1. The uptake of the nanoparticles was followed by adding
a fluorescent tag. Hsu, Delaittre and co-workers compared
their systems with BPA, in terms of solubility and boron
content, and found that such nanoparticles are indeed more
advantageous than the small molecule.
Scheme 2 Self-assembly into vesicles of a fluorescent carborane-con-
jugated POEGMA.
Fig. 5 Schematic illustration of HVJ-E surface modification by a ben-
zoxaborole-containing polymer. Reproduced from ref. 24 with per-
mission from Taylor & Francis, copyright 2019.
Fig. 6 Schematic illustration of the POEGM0-b-poly(4-pinacolboronyl-
benzyl methacrylate). R1 = 4-phenylboronate pinacol ester, R2 = fluor-
escein. Reproduced from ref. 26 with permission from the Royal Society
of Chemistry, copyright 2020.
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Peptides have also been used to incorporate boron atoms
and deliver them to specific receptors. Barth, Soloway and co-
workers functionalised poly(DL-lysine) with isocyanato-closo-
dodecaborate, which was further linked to a monoclonal
antibody.27,28 This polymeric linker was used to minimise the
reduction of the immunoreactivity of the monoclonal antibody
in the presence of boron clusters. The bioconjugates contained
more than 1000 boron atoms per macromolecule and retained
between 40 and 90% of the immunoreactivity, thus making
them potentially suitable as delivery systems for BNCT. This
initial approach was, however, limited by polymers with a
molar mass dispersity relatively important, which in turn led
to heterogeneity in the number of boron atoms present.
In 2020, Beck-Sickinger and co-workers described the use of
a peptide conjugate to selectively target the human Y1 (hY1)
receptor, which is overexpressed on cancer cells.29 This
36-amino acid peptide was functionalised on two lysines with
deoxygalactopyranosyl-modified carborane building blocks.
These saccharide moieties ensured appropriate aqueous solu-
bility and allowed the incorporation of up to 80 boron atoms
per peptide. In vitro studies on MCF-7 cells (human breast
cancer cells) showed that the bioconjugate systems exhibited
high receptor activity and internalisation at the hY1 receptors,
selectivity against other hY receptor subtypes and low intrinsic
cytotoxicity.
Dendrimers. Dendrimers have received a lot of attention as
drug-delivery systems, owing to their large number of periph-
ery sites available for functionalisation and the well-advanced
methodologies available to synthesise them. Functionalisation
allows for the introduction of a variety of molecules, ranging
from boron-containing synthons, to polymer chains and bio-
molecules such as antibodies.
Poly(amidoamine) (PAMAM) dendrimers have particularly
been studied.30 Barth and co-workers have extensively studied
boronated PAMAM dendrimers conjugated with various bio-
molecules such as monoclonal antibodies.31 Monoclonal anti-
bodies are promising in the treatment of cancers. By recognis-
ing specific proteins on the membrane of cancer cells, mono-
clonal antibodies can selectively target cancer cells. The epi-
dermal growth factor receptor (EGFR) gene is often amplified
in human glioblastomas, with tumour cells having up to 100
times more receptors than normal cells. Such an EGPR can
therefore be used as a target, using EGF bioconjugates to
deliver boron atoms to cancer cells. Barth and coworkers devel-
oped several methodologies to boronate EGF,32 such as using
the thiol–maleimide “click” chemistry reaction. Starburst den-
drimers composed of repetitive polyamidoamino (PAMAM)
groups were functionalised on their terminal amine groups by
an isocyanato polyhedral borane and further functionalised
with a thiol group to react with the maleimide groups of EGF
derivatives (Fig. 7). The stable bioconjugates bearing a fourth-
generation dendrimer were shown to contain 960 atoms of
boron per molecule.33 By taking into account the density of
receptor sites on the cancer cells, and the affinity constant, the
authors determined that each molecule of the antibody must
deliver 1000 atoms of boron to attain a critical local boron con-
centration. The boron concentrations in F98WT and F98EGFR
cells (cancer brain rat cells) implanted in rats were found to be
9.2 and 21.1 μg g−1 of tumour 24 hours after injection, while
no boron could be detected in the liver, spleen, kidneys, brain
and blood. The mean survival time (MST) in the F98EGFR rat
model after BNCT treatment was longer with the bioconjugate
compared to BPA (45 versus 39 days).34
The initial focus of BNCT was the treatment of glioblasto-
mas, which could not be treated by other therapeutic modal-
ities. Therefore, the ability to cross the blood–brain barrier
(BBB) needed to be investigated. In 2002, Barth and co-workers
examined the use of convection-enhanced delivery (CED) to
improve the tumour uptake of a heavily boronated dendrimer
EGF bioconjugate.35 Indeed, the high molecular weight of the
EGF moiety is a limiting factor for accessing the brain.
Convection-enhanced delivery is a delivery method that can
bypass the BBB and introduce agents directly into the extra-
vascular space of the central nervous system. Results on
F98EGFR glioma-bearing rats showed that the delivery of these
high-molecular-weight boronated dendrimer EGF bioconju-
gates was improved compared to intravenous injection with an
increased volume of distribution within the tumour.
The antibody IB16-6 was also conjugated by Barth, Soloway
and co-workers to PAMAM dendrimers, which were functiona-
lised with a decaborane cluster.36 The antibody was linked to
the outer shell of the dendrimer by a derivatised site, which
prevents a random attachment and retains its localising pro-
perties in in vitro studies. However, in vivo studies on rats
bearing B16 melanomas showed a tendency to accumulate in
the liver and spleen and a lack of specificity for the tumour.
To further enhance the efficacy of BNCT, the vascular endo-
thelial growth factor (VEGF) receptors, which are overexpressed
in tumour neovasculature, can also be targeted.37 Barth and
co-workers used the coupling strategy reported for EGFR bio-
conjugates to bind four boronated PAMAM dendrimers to one
VEGF molecule (Fig. 8).38 The activity of the protein was not
affected by a large increase in molecular weight. By labelling
these bioconjugates with the near-IR Cy5 dye, and following
internalisation via receptor-mediated endocytosis, boron could
Fig. 7 Boron-containing PAMAM dendrimer linked to an antibody.
Adapted from ref. 31 with permission from the American Chemical
Society, copyright 2004.
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be imaged in the perinuclear region where angiogenesis is the
most active in the 4T1 breast carcinoma mouse tumour model.
The biodistribution of dendritic prodrugs can be improved
by adding poly(ethylene glycol) (PEG) chains to the surface of
dendrimers. Indeed, by coating the surface of drug-delivery
systems with flexible and hydrophilic polymers (PEG and poly-
oxazoline), longer circulation times (i.e., stealth properties)
have been observed, which can then lead to a higher prob-
ability to access tumour sites and their leaky vasculature.39 In
2003, Tjarks and co-workers functionalised a series of boro-
nated G3 PAMAM dendrimers bearing PEG chains and folic
acid (FA), to minimise hepatic uptake and increase receptor
targeting, respectively.40 The best results in terms of tumour
selectivity were obtained with a G3 boronated dendrimer
coated with only one PEG2000, while a few shorter chains
(PEG500 or PEG750) did not effectively shield the dendrimer
surface and a large number of short PEG chains did not shield
the dendrimer from opsonisation. However, both hepatic and
renal uptakes were still very high.
In 2012, Hosmane and co-workers synthesised phenylene-
cored small dendrimers containing three, six or nine peri-
pheral o-carborane clusters (Fig. 9).41 The in vitro biological
evaluation of the dendrimer with nine carborane units showed
that it accumulated either in human hepatocellular carcinoma
cells or bound to their surface, with a boron concentration of
up to 2540 ng per 5 × 105 cells after 20 hours of incubation.
Such a concentration corresponds to about 1.5 mg of boron
per gram of tumour, which, by taking into account the natural
abundance of 10B, still gives a value of 300 μg g−1, above the
30 μg of 10B per g of tumour required for efficient BNCT. No
further studies have been carried out on such systems.
Hosmane and co-workers also explored the use of a different
core, made of gold nanoparticles, which is then functionalised
by dendrons with thiol moieties on the apex and with carbor-
ane and PEG units at the periphery.42 These water-soluble gold
nanoparticles have, however, not been tested as BNCT
materials.
The bifunctional carborane synthon strategy developed by
Adronov and co-workers for dendritic polymers was also used
to incorporate carborane units into an aliphatic polyester den-
drimer (Fig. 10).43 Such localisation of the carborane allows
for the presence of peripheral hydrophilic groups, which
improves the water solubility of the dendrimer and masks the
hydrophobic carborane unit. The 2,2-bis(hydroxymethyl)propa-
noic acid (bis-MPA) core of the dendrimers, which is biocom-
patible, non-immunogenic, non-toxic, water soluble, and toler-
ated in vivo, was functionalised by a carborane unit. The
second functional and opposite site of this carborane unit was
further used to incorporate more bis-MPA units and therefore
to increase the overall size of the dendrimer and its aqueous
solubility with a value of 8 mg mL−1 observed for the dendri-
mer containing four carborane units and 64 peripheral
hydroxyl groups. Neutron activation experiments on the various
dendrimers fully solubilised in THF revealed that they all
exhibit the characteristic gamma radiation signature at 480 keV,
which confirms that boron neutron capture events take place.
Analysis of the samples after six hours of irradiation showed no
degradation, which is expected given only 0.01% of the 10B
atoms reacted within the time frame of the experiment.
Dendritic polymers. Dendritic polymers are highly branched
polymers with three-dimensional architectures. There are
Fig. 10 Structure of the fourth-generation bis-MPA dendrimer bearing
four bifunctional carborane units and 64 hydroxyl groups. Adapted from
ref. 43 with permission from the American Chemical Society, copyright
2005.
Fig. 8 VEGF-containing bioconjugate made of G5 PAMAM dendrimers
functionalised by the near-IR dye Cy5 and the boron cluster dodecabo-
rate (a total of 105–110 boron clusters per dendrimer).
Fig. 9 Phenylene-cored carborane dendrimers prepared by click
chemistry.
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many sub-classes: dendrimers (as discussed above), hyper-
branched polymers, multi-arm star polymers, dendronized
polymers, hypergrafted polymers and dendritic-linear block
copolymers. Dendritic polymers exhibit unique chemical and
physical properties derived from their architecture: they
possess a large number of terminal functional groups, low vis-
cosity and good solubility. The fine-tuning of their size, com-
position, degree of branching, and further functionalisation
with targeting ligands or imaging agents makes them suitable
candidates for biomedical applications.44
Hawthorne and co-workers developed closomer species,
which are dendrimer-like structures.45 The core of the struc-
ture was made of the rigid icosahedral boron scaffold [closo-
B12(OH)12]
2− anion while the shell consisted of twelve o-carbor-
ane units linked through ester and ether functions to the
central boron core. Aqueous solubility was improved by modi-
fying the pendant carborane units. These unimolecular nano-
particles (with a diameter of around 3 nm) were well tolerated
by mice and are not toxic. Biodistribution data were collected
on mice bearing EMT6 tumours (breast cancer cells) and
showed that the maximum tumour boron concentration was
achieved 24 hours post-injection and reached 10.5 μg B g−1 of
tumour, with a tumour-to-blood ratio of 9.4.
In 2008, Adronov and co-workers extended their library of
synthons containing carborane units by functionalising one
side of the carborane with a styrene entity and the other side
with the aliphatic polyester dendrimer backbone, which is
water soluble, biocompatible and biodegradable.46 After nitr-
oxide-mediated polymerisation and divergent growth of the
dendrons, high-molecular-weight polymers with narrow dis-
persity were obtained, with a theoretical boron content of
around 12% and a water solubility of around 1 mg mL−1
(Fig. 11).
Boron-loaded systems
Dendrimers. Dendrimers, owing to their unique 3D struc-
ture, contain cavities between branches. These cavities can be
used to encapsulate different materials, both organic and in-
organic, and to perform various reactions.47
A monoclonal antibody directed against the stem cell
marker CD133, frequently expressed in the membrane of
glioma stem cells, was used by Sun et al. to deliver a heavily
boronated poly(amido amine) dendrimer.48 BSH was loaded
into the voids available within the structure of the PAMAM
dendrimer (Fig. 12). Glioma stem cells are resistant cells that
escape conventional radiotherapy- and chemotherapy-induced
cell death and lead to tumour regrowth. In vitro studies on
CD133+ and CD133− SU2 (glioma stem) cells confirmed that
more than 109 boron atoms were delivered to the CD133+ SU2
cells, with some selectivity compared to the CD133− SU2 cells,
therefore reaching the minimum amount of boron per cell
established as needed for BNCT. In vivo studies on BALB/c
mice bearing intracerebral CD133+ SU2 cells confirmed the
boron uptake and these selectivity and biodistribution studies
showed the influence of the nanocarrier on the boron ratio
between the tumour and the brain or the blood. BNCT treat-
ment led to a significantly longer survival time in BALB/c mice
bearing intracerebral CD133+ SU2 cells compared to that of
CD133− SU2 cells. The MST was even longer when both the
boron-containing bioconjugate and free BSH were adminis-
tered before neutron irradiation.
Virus. HVJ-E loading capability has been used by Lee and co-
workers to deliver BSH for the treatment of liver tumours.49
BSH was incorporated into an inactive form of the virus, which
is used as a carrier agent following a standard procedure that
allows the incorporation of small molecules inside the virus
envelope. Then, a natural polymer, cationised gelatin, was
mixed with HVJ-E to reduce its hemagglutinating activity,
which is a limiting factor for the in vivo circulation of HVJ-E in
the bloodstream. This allowed its use for systemic adminis-
tration. In mice bearing multiple LM8G5 liver tumours, the
use of this carrier was shown to increase the concentration of
boron in the cytoplasm and the nucleus of tumour cells and
the tumour/normal liver ratio compared to free BSH.
BNCT experiments in vivo with the boron-loaded bioconjugate
exhibited a significant increase of the mean survival time of
tumour-bearing mice compared to BSH at a comparable
dosage of 10B.
Liposomes. Liposomes have extensively been used in thera-
peutic and diagnostic applications owing to their unique pro-
perties as they can entrap hydrophilic drugs and prevent their
premature release in the bloodstream. Liposomes became the
first nanomedicines in FDA clinical trials with the approval in
1995 for Doxil®, a PEGylated liposome formulation that encap-
sulates doxorubicin.50
The first example of a 10BSH-encapsulated liposome conju-
gated with a monoclonal antibody was reported in 1989 by
Fig. 11 Styrenic dendritic polymer bearing carborane units functiona-
lised with a bis-MPA dendron.
Fig. 12 Monoclonal antibody targeting nanoparticle containing BSH
encapsulated within the PAMAM dendrimer.
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Yanagië and co-workers. Up to 1.3 × 104 10B atoms were encap-
sulated per antibody-conjugated liposome.51 The immunolipo-
somes were shown to in vitro selectively reach tumour cells and
to suppress growth after thermal neutron irradiation.
In 1992, Hawthorne and co-workers encapsulated different
borane anions inside phospholipid liposomes using their
water-soluble sodium salts.52 In vivo studies in tumour-bearing
mice revealed that good affinity of the liposomes for tumour
cells was observed despite the absence of targeting entities.
Boron concentrations in the tumour tissue were found to
reach the therapeutic range (15 μg of boron per g of tumour)
for boron clusters containing 20 atoms of B.
Various boron-encapsulated liposomes have been developed
during the last few decades, however, most formulations did
not contain enough boron within their core, which prevents
them from reaching the therapeutic range needed for BNCT.53
In 2019, Krishnan, Prasad and co-workers designed an azo-
lectin phospholipid-based liposome system to encapsulate
both small boron nanoparticles and the near-infrared fluo-
rescent dye Cy5 (Fig. 13).54 The boron nanoparticles (hydro-
dynamic diameter of 15 nm) were prepared using CO2 laser-
induced pyrolysis mixtures of B2H6 and SF6 and loaded inside
the liposomes by the water-in-oil emulsion method. The target-
ing moiety FA was conjugated on the surface of the liposomes
by EDC/NHS coupling, which increased the hydrodynamic dia-
meter of the liposomes from 100 to 120 nm. Cellular uptake
studies were performed in rat C6 glioblastoma cells, with an
enhanced uptake for the FA-conjugated liposomes. The ability
of the liposomes to cross the BBB was determined with a 2D
in vitro BBB model made of human brain microvascular endo-
thelial cells and normal human astrocytes. While both non-
and FA-conjugated liposomes crossed the BBB without
damage to their structure, the crossing was more effective for
the FA-conjugated liposomes, as illustrated by the higher
boron content in cells determined by ICP-MS (3.7 pg per cell
and 1.5 pg per cell, and only 0.6 pg per cell for the free boron
nanoparticles). The two liposome systems therefore allow an
uptake per cell that exceeds the recommended concentration
of boron for effective BNCT. Finally, the toxicity of the lipo-
somes was determined to be negligible.
Conclusions
BNCT has not yet gained worldwide acceptance by physicians
to treat cancer patients on a daily basis. There are various
reasons for this. The first one is the access to neutron sources.
Until recently, only nuclear reactors could deliver neutrons of
the correct energy. Accelerators built on hospital sites are now
suitable as neutron sources for BNCT12 and have been built in
a few countries around the globe (for example, Japan and
Finland).55 The second one is the lack of new and more
effective boron delivery agents. BPA and BSH have been the
only two compounds so far to show in vivo results promising
enough in terms of biodistribution, toxicology and therapeutic
effect, which then led to human studies and their clinical use.
The formidable advances that have happened in the last few
decades in the fields of polymer chemistry and formulation for
designing drug delivery systems will undoubtedly benefit the
BNCT community. Thirdly, BNCT studies have so far mainly
focused on brain tumours (with an emphasis on high-grade
gliomas), with more limited studies on melanomas and recur-
rent head and neck tumours.56 Other hard-to-treat cancers
could be expected to be treated using BNCT, based on either
current treatment modalities not anatomically suitable or lack
of efficient treatment modalities. The author believes that
from the pool of polymeric systems, boron-conjugated poly-
mers are highly promising, especially as some polymer–drug
conjugate therapeutics have already been approved. However,
the path for designing a suitable system is not straightforward,
especially for polymer-small drug conjugates, for which the
EPR effect seems to play a vital role. Therefore, having a system
loaded with enough boron is one criterion, but ensuring that
this system reaches only the targeted cells in quantities high
enough is another challenge. Labelling and targeting moieties
will most certainly need to be taken into account in the design
of successful BNCT carriers.
Abbreviations
ATRP Atom transfer radical polymerisation
BBB Blood–brain barrier
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EGFR Epithermal growth factor receptor
EPR Enhanced permeability and retention
FA Folic acid
Gn Generation n of a dendron
HVJ-E Hemagglutinating virus of Japan Envelope
ICP-MS Inductively coupled plasma-mass spectrometry
MST Mean survival time
OEGMA Oligo(ethylene glycol)methyl methacrylate
PAMAM Poly(amidoamine)
PCL Poly(caprolactone)
Fig. 13 Schematic representation of the boron-encapsulated liposome
synthesised by Krishnan, Prasad and co-workers.
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